DNMT1 and acute myeloid leukemia: Although meta-analysis suggested that lenalidomide + azacitidine (DNMT inhibitor) might be superior to azacitidine monotherapy in AML therapy, randomized clinical trial (RCTs) negated the additional beneficial effect of this combination [98, 99].